Lupus erythematosus
☆ In anno 2022 Stiftung Warentest ex Germania provenit, satisfactio consumptoria cum ModelDerm paulo minus fuit quam cum consultationibus telemedicinis solutis.
Ut leviter erythema purpureum apparet.
papilio temerarium quod typice in facie apparet.
relevance score : -100.0%
ReferencesProvocationes diagnosticae distinguunt cutaneum lupus erythematosum (CLE) a lupus erythematoso systemico cum implicatione cutis. Recentes studia illustrant causas geneticas, ambientales et immunologicas quae CLE incitant. Inductio medicamentosa speciatim emersit ut una ex maximis factoribus incitantibus CLE. Curatio includit therapias topicas et systemicas, inter quas biologicae (belimumab, rituximab, ustekinumab, anifrolumab, BIIB059) cum efficacia demonstrata in studiis clinicis.
Diagnostic challenges exist in better defining cutaneous lupus erythematosus (CLE) as an independent disease distinct from systemic lupus erythematosus with cutaneous features and further classifying CLE based on clinical, histological, and laboratory features. Recent mechanistic studies revealed more genetic variations, environmental triggers, and immunologic dysfunctions that are associated with CLE. Drug induction specifically has emerged as one of the most important triggers for CLE. Treatment options include topical agents and systemic therapies, including newer biologics such as belimumab, rituximab, ustekinumab, anifrolumab, and BIIB059 that have shown good clinical efficacy in trials.
Diagnostic challenges exist in better defining cutaneous lupus erythematosus (CLE) as an independent disease distinct from systemic lupus erythematosus with cutaneous features and further classifying CLE based on clinical, histological, and laboratory features. Recent mechanistic studies revealed more genetic variations, environmental triggers, and immunologic dysfunctions that are associated with CLE. Drug induction specifically has emerged as one of the most important triggers for CLE. Treatment options include topical agents and systemic therapies, including newer biologics such as belimumab, rituximab, ustekinumab, anifrolumab, and BIIB059 that have shown good clinical efficacy in trials.
Cutaneous lupus erythematosus (CLE) varias quaestiones cutaneas affert, quarum aliquas ad problemata sanitatis latioris coniungi potest. Classificatur in varias species, ut CLE acuta (ACLE), CLE subacuta (SCLE) et CLE chronica (CCLE). CCLE includit discoid lupus erythematosus (DLE), lupus erythematosus profundus (LEP), chilblain cutaneous lupus et lupus tumidus.
Cutaneous lupus erythematosus (CLE) encompasses a wide range of dermatologic manifestations, which may or may not be associated with the development of systemic disease. Cutaneous lupus is divided into several sub-types, including acute CLE (ACLE), sub-acute CLE (SCLE) and chronic CLE (CCLE). CCLE includes discoid lupus erythematosus (DLE), LE profundus (LEP), chilblain cutaneous lupus and lupus tumidus.
Cutaneous lupus erythematosus (CLE) encompasses a wide range of dermatologic manifestations, which may or may not be associated with the development of systemic disease. Cutaneous lupus is divided into several sub-types, including acute CLE (ACLE), sub-acute CLE (SCLE) and chronic CLE (CCLE). CCLE includes discoid lupus erythematosus (DLE), LE profundus (LEP), chilblain cutaneous lupus and lupus tumidus.
Lupus erythematosus est coetus morborum autoimmunium, qui partes corporis afficere possunt. Quaedam genera, sicut systemic lupus erythematosus (SLE), multos organa impingunt; aliae, ut cutaneous lupus erythematosus (CLE), praesertim cutem afficiunt. Varias species CLE distinguuntur ex mixtura signorum clinicorum, examenibus et testibus sanguinis, sed inter homines magna est variatio. Problemata cutis saepe explicantur factoribus, ut expositione solis, fumo, aut quibusdam medicamentis.
Lupus erythematosus comprises a spectrum of autoimmune diseases that may affect various organs (systemic lupus erythematosus [SLE]) or the skin only (cutaneous lupus erythematosus [CLE]). Typical combinations of clinical, histological and serological findings define clinical subtypes of CLE, yet there is high interindividual variation. Skin lesions arise in the course of triggers such as ultraviolet (UV) light exposure, smoking or drugs
Lupus erythematosus comprises a spectrum of autoimmune diseases that may affect various organs (systemic lupus erythematosus [SLE]) or the skin only (cutaneous lupus erythematosus [CLE]). Typical combinations of clinical, histological and serological findings define clinical subtypes of CLE, yet there is high interindividual variation. Skin lesions arise in the course of triggers such as ultraviolet (UV) light exposure, smoking or drugs
Causa lupus erythematosus non liquet. In geminis idem, si unum affectum est, probabilitas alterius est 24 %. Hormonae sexus feminarum, sol, fumigatio, defectus Vitaminæ D, et quaedam infectiones etiam creduntur periculum augere.
Curationes includunt NSAIDs, corticosteroides, immunosuppressantes, hydroxychloroquinas et methotrexatum. Etiam si corticosteroides efficaces sunt, usus diuturnus eorum potest habere effectus adversos.